Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2013

01-11-2013 | Erratum

Erratum to: The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England

Authors: Leonardo Simonella, Karen Canfell

Published in: Cancer Causes & Control | Issue 11/2013

Login to get access

Excerpt

Unfortunately, the original publication of the article included error in the first sentence of the “Background” section. The corrected sentence should read “Organized screening was rolled out in England in 1988 and in Australia and in New Zealand in 1991.” …
Metadata
Title
Erratum to: The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England
Authors
Leonardo Simonella
Karen Canfell
Publication date
01-11-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0276-z

Other articles of this Issue 11/2013

Cancer Causes & Control 11/2013 Go to the issue

Original paper

Lifestyle, dietary factors, and antibody levels to oral bacteria in cancer-free participants of a European cohort study

Original Paper

Menstrual and reproductive characteristics and breast density in young women

Brief Report

Non-steroidal anti-inflammatory drug use and brain tumour risk: a case–control study within the Clinical Practice Research Datalink

Original Paper

Lung cancer risk from radon in Ontario, Canada: how many lung cancers can we prevent?

Original Paper

Differences in the cancer burden among foreign-born and US-born Arab Americans living in metropolitan Detroit

Original Paper

The association of ultraviolet radiation-B (305 nm), season of diagnosis, and latitude on the survival outcome of prostate cancer in the high UV environment of Australia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits